Limited availability of information on antibiotics and lack of availability of appropriate antibiotics were cited as important challenges for appropriate antibiotic selection.
While incidence of community-associated and healthcare-associated community-onset MRSA bacteremia declined during the pandemic, hospital-onset cases rose substantially.
Antibiotic use in the first 3 month of life was associated with a 23% increase in risk of early puberty in girls.
A study of bloodstream infections in Ontario finds attributable mortality due to AMR over 5 years was 896 deaths, or 1.2 per 100,000 population per year.
The AMR Industry Alliance has updated its Antibiotic Manufacturing Standard to be more aligned with WHO antibiotic manufacturing guidelines.
The median treatment duration for uncomplicated gram-negative BSIs at 24 US hospitals was 11 days, with marked variation among hospitals.
Analysis of hospitalized patients with community-acquired pneumonia links azithromycin to lower mortality and more hospital-free days compared with doxycycline in combination with beta-lactams.
Zevtera, an advanced-generation cephalosporin, is available for treating Staphylococcus aureus bacteremia and 2 other types of bacterial infection.
A comparative effectiveness study finds that patients treated with laLGPs had similar outcomes as those who received standard-of-care antibiotics.
The Swiss drugmaker says the safety and efficacy of zosurabalpin will be investigated in a study involving 400 patients with carbapenem-resistant A baumannii infections.
Two novel antibiotic candidates for gonorrhea received funding to advance into clinical trials.
A retrospective analysis of hospitalized VA patients finds that prior flu or RSV infection more than doubled the odds of subsequent Streptococcus pneumoniae infection.
Data from 11 Wellcome-funded research projects show that the relationship between vaccination and its impact on AMR is "rarely straightforward."
A review and meta-analysis finds a 33% pooled prevalence of non-prescription antibiotic use in kids under 5 in low- and middle-income countries.
Estimates varied from 2008 through 2018, with RSV-associated antibiotic prescribing exceeding 10% in peak RSV years and flu-associated prescribing exceeding 20% in peak flu years.
